| 摘要: |
| 地西他滨是天然核苷2’-脱氧胞苷酸的一种类似物。2008年进口中国用于治疗骨髓增生异常综合征(MDS),2012年9月获得欧盟批准上市,用于治疗未经治疗或复发的急性髓性白血病(AML)。本文主要综述其近年国内外的临床研究进展。 |
| 关键词: 地西他滨 抗肿瘤 临床研究 |
| DOI:10.13506/j.cnki.jpr.2017.05.015 |
| 基金项目: |
|
|
|
| Clinical progress of Decitabine |
| YANG Tongjiang,CHEN Yancheng,XIE Lili,SHAN Yanqiang |
| (Qilu Pharmaceutical(Hainan)Co.,Ltd.,Haikou 570314,China) |
| Abstract: |
| Decitabine is a nucleoside metabolic inhibitor indicated for treatment of patients with myelodysplastic syndromes (MDS).In September 2012,the European Medicines Agency approved as a treatment for acute myelogenous leukemia.The advancement of Decitabine in current clinic researches are reviewed in this article. |
| Key words: Decitabine Anticancer Clinical progress |